Literature DB >> 16533716

Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits.

Tobias Wunberg1, Martin Hendrix, Alexander Hillisch, Mario Lobell, Heinrich Meier, Carsten Schmeck, Hanno Wild, Berthold Hinzen.   

Abstract

Drug-like and lead-like hits derived from HTS campaigns provide good starting points for lead optimization. However, too strong emphasis on potency as hit-selection parameter might hamper the success of such projects. A detailed absorption, distribution, metabolism, excretion and toxicology (ADME-Tox) profiling is needed to help identify hits with a minimum number of (known) liabilities. This is particularly true for drug-like hits. Herein, we describe how to break down large numbers of screening hits and we provide a comprehensive overview of the strengths and weaknesses for each structural class. The overall profile (e.g. ligand efficiency, selectivity and ADME-Tox) is the distinctive feature that will define the priority for follow-up.

Entities:  

Mesh:

Year:  2006        PMID: 16533716     DOI: 10.1016/S1359-6446(05)03700-1

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  29 in total

1.  Thermodynamic Proxies to Compensate for Biases in Drug Discovery Methods.

Authors:  Sean Ekins; Nadia K Litterman; Christopher A Lipinski; Barry A Bunin
Journal:  Pharm Res       Date:  2015-08-27       Impact factor: 4.200

2.  DOCK 6: combining techniques to model RNA-small molecule complexes.

Authors:  P Therese Lang; Scott R Brozell; Sudipto Mukherjee; Eric F Pettersen; Elaine C Meng; Veena Thomas; Robert C Rizzo; David A Case; Thomas L James; Irwin D Kuntz
Journal:  RNA       Date:  2009-04-15       Impact factor: 4.942

3.  Quantifying structure and performance diversity for sets of small molecules comprising small-molecule screening collections.

Authors:  Paul A Clemons; J Anthony Wilson; Vlado Dančík; Sandrine Muller; Hyman A Carrinski; Bridget K Wagner; Angela N Koehler; Stuart L Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-11       Impact factor: 11.205

4.  Discovery of novel bacterial elongation condensing enzyme inhibitors by virtual screening.

Authors:  Zhong Zheng; Joshua B Parsons; Rajendra Tangallapally; Weixing Zhang; Charles O Rock; Richard E Lee
Journal:  Bioorg Med Chem Lett       Date:  2014-04-02       Impact factor: 2.823

Review 5.  Advances in computationally modeling human oral bioavailability.

Authors:  Junmei Wang; Tingjun Hou
Journal:  Adv Drug Deliv Rev       Date:  2015-01-09       Impact factor: 15.470

Review 6.  New agents for the treatment of drug-resistant Mycobacterium tuberculosis.

Authors:  Daniel T Hoagland; Jiuyu Liu; Robin B Lee; Richard E Lee
Journal:  Adv Drug Deliv Rev       Date:  2016-05-02       Impact factor: 15.470

Review 7.  Hit and lead criteria in drug discovery for infectious diseases of the developing world.

Authors:  Kei Katsuno; Jeremy N Burrows; Ken Duncan; Rob Hooft van Huijsduijnen; Takushi Kaneko; Kiyoshi Kita; Charles E Mowbray; Dennis Schmatz; Peter Warner; B T Slingsby
Journal:  Nat Rev Drug Discov       Date:  2015-10-05       Impact factor: 84.694

8.  Inhibition of noroviruses by piperazine derivatives.

Authors:  Dengfeng Dou; Guijia He; Sivakoteswara Rao Mandadapu; Sridhar Aravapalli; Yunjeong Kim; Kyeong-Ok Chang; William C Groutas
Journal:  Bioorg Med Chem Lett       Date:  2011-11-15       Impact factor: 2.823

9.  Identification of Small Molecule Inhibitors of Clostridium perfringens ε-Toxin Cytotoxicity Using a Cell-Based High-Throughput Screen.

Authors:  Michelle Lewis; Charles David Weaver; Mark S McClain
Journal:  Toxins (Basel)       Date:  2010-07-01       Impact factor: 5.075

10.  The pK(a) Distribution of Drugs: Application to Drug Discovery.

Authors:  David T Manallack
Journal:  Perspect Medicin Chem       Date:  2007-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.